What is APIMEDS PHARMACEUTICALS US INC's earnings per share (EPS)?

APIMEDS PHARMACEUTICALS US INC (APUS) reported diluted earnings per share of $-0.55 for fiscal year 2025. This represents a -205.6% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

APIMEDS PHARMACEUTICALS US INC Financials

APUS

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows APIMEDS PHARMACEUTICALS US INC (APUS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI APUS FY2025 2026-05-26

FY2025 looks like an externally funded balance-sheet reset, with new capital and assets reshaping the company faster than operations.

Between FY2024 and FY2025, total assets moved from $13K to $164.2M and equity swung from -$1.36M to $153.3M, so the main story is recapitalization rather than improving self-funded operations. In FY2025, $20.6M of financing cash flow almost exactly absorbed -$8.9M of operating cash burn and -$10.1M of investing outflow, which is why year-end cash still sat at only $1.6M.

The balance sheet now looks solvent on paper: liabilities were only $10.8M against $153.3M of equity and a debt-to-equity ratio of 0.1x, but near-term liquidity is much tighter. A 1.3x current ratio and just $1.6M of cash against $10.7M of current liabilities mean most of the apparent strength is not sitting in immediately spendable cash.

FY2025 spending was overhead-heavy: SG&A was $10.3M versus $1.6M of R&D, while capital spending was only $57K. That mix suggests the cash drain came mainly from maintaining the corporate platform and other operating costs, not from a large manufacturing build-out or unusually heavy reinvestment.

Financial Health Signals

Financial health score pending refresh

We are recalculating APIMEDS PHARMACEUTICALS US INC's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.

Piotroski F-Score Partial

1/5

APIMEDS PHARMACEUTICALS US INC passes 1 of 5 computable financial strength tests (4 of the nine could not be computed from available data). No profitability signals pass, 1 of 2 leverage/liquidity signals pass.

Earnings Quality Low Quality

1.49x

For every $1 of reported earnings, APIMEDS PHARMACEUTICALS US INC generates $1.49 in operating cash flow (-$8.9M OCF vs -$6.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-42.1x

APIMEDS PHARMACEUTICALS US INC earns $-42.1 in operating income for every $1 of interest expense (-$11.9M vs $283K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$11.9M

APIMEDS PHARMACEUTICALS US INC's EBITDA was -$11.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Net Income

-$6.0M

APIMEDS PHARMACEUTICALS US INC reported -$6.0M in net income in fiscal year 2025.

EPS (Diluted)

$-0.55

YoY-205.6%

APIMEDS PHARMACEUTICALS US INC earned $-0.55 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 205.6% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$9.0M

APIMEDS PHARMACEUTICALS US INC generated -$9.0M in free cash flow in fiscal year 2025, representing cash available after capex.

Cash & Debt

$1.6M

YoY+47270.6%

APIMEDS PHARMACEUTICALS US INC held $1.6M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

13M

YoY+59.1%

APIMEDS PHARMACEUTICALS US INC had 13M shares outstanding in fiscal year 2025. This represents an increase of 59.1% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-3.9%

APIMEDS PHARMACEUTICALS US INC's ROE was -3.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.

Capital Allocation

R&D Spending

$1.6M

APIMEDS PHARMACEUTICALS US INC invested $1.6M in research and development in fiscal year 2025.

Share Buybacks

N/A

Capital Expenditures

$57K

APIMEDS PHARMACEUTICALS US INC invested $57K in capex in fiscal year 2025, funding long-term assets and infrastructure.

APUS Income Statement

Metric	FY25	FY24	FY23
Revenue	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A
R&D Expenses	$1.6M	N/A	$99K
SG&A Expenses	$10.3M	N/A	$649K
Operating Income	-$11.9M	N/A	-$747K
Interest Expense	$283K	N/A	$38K
Income Tax	N/A	N/A	N/A
Net Income	-$6.0M	N/A	-$778K
EPS (Diluted)	$-0.55-205.6%	$-0.18-5.9%	$-0.17

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$901K	N/A	$620K-4.9%	$652K	N/A	N/A	N/A	N/A
SG&A Expenses	$11.3M	N/A	$1.2M-39.1%	$2.0M+452.2%	$364K	N/A	$300K-29.9%	$428K
Operating Income	-$12.2M	N/A	-$1.8M+30.8%	-$2.7M-631.1%	-$364K	N/A	-$300K+29.9%	-$428K
Interest Expense	$8K	N/A	$6K+104.4%	$3K-99.6%	$851K	N/A	$33K+47.5%	$22K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$35.1M	N/A	-$1.8M+33.1%	-$2.7M-561.6%	-$402K	N/A	-$333K+26.0%	-$449K
EPS (Diluted)	$-2.26	N/A	$-0.14+46.2%	$-0.26-420.0%	$-0.05	N/A	$-0.04+33.3%	$-0.06

APUS Balance Sheet

Metric	FY25	FY24	FY23
Total Assets	$164.2M+1257338.4%	$13K-96.9%	$422K
Current Assets	$14.0M+106998.6%	$13K-96.9%	$422K
Cash & Equivalents	$1.6M+47270.6%	$3K-99.2%	$410K
Inventory	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A
Total Liabilities	$10.8M+690.3%	$1.4M+251.4%	$390K
Current Liabilities	$10.7M+945.2%	$1.0M+730.7%	$123K
Long-Term Debt	N/A	N/A	N/A
Total Equity	$153.3M+11391.2%	-$1.4M-4361.6%	$32K
Retained Earnings	-$10.4M-136.6%	-$4.4M-46.3%	-$3.0M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$141.2M-14.0%	$164.2M+1675.0%	$9.3M-12.3%	$10.5M+3957.9%	$260K+1890.5%	$13K	N/A	N/A
Current Assets	$13.2M-5.9%	$14.0M+53.9%	$9.1M-12.2%	$10.3M+3882.1%	$260K+1890.5%	$13K	N/A	N/A
Cash & Equivalents	$980K-40.2%	$1.6M-76.6%	$7.0M-20.0%	$8.7M+3388.1%	$250K+7148.4%	$3K-87.0%	$27K-58.0%	$63K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$14.7M+35.7%	$10.8M+894.7%	$1.1M+34.7%	$809K-60.0%	$2.0M+47.3%	$1.4M	N/A	N/A
Current Liabilities	$14.6M+36.2%	$10.7M+882.8%	$1.1M+34.7%	$809K-54.3%	$1.8M+72.8%	$1.0M	N/A	N/A
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$126.5M-17.5%	$153.3M+1779.1%	$8.2M-16.2%	$9.7M+653.1%	-$1.8M-29.6%	-$1.4M-29.8%	-$1.0M-46.6%	-$714K
Retained Earnings	-$45.5M-337.3%	-$10.4M-12.5%	-$9.2M-23.9%	-$7.5M-55.5%	-$4.8M-9.2%	-$4.4M	N/A	N/A

APUS Cash Flow Statement

Metric	FY25	FY24	FY23
Operating Cash Flow	-$8.9M	N/A	-$628K
Capital Expenditures	$57K	N/A	N/A
Free Cash Flow	-$9.0M	N/A	N/A
Investing Cash Flow	-$10.1M	N/A	N/A
Financing Cash Flow	$20.6M	N/A	$1.0M
Dividends Paid	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$2.1M+45.8%	-$3.8M-121.2%	-$1.7M+48.6%	-$3.4M-16446.5%	-$20K	N/A	-$187K-1.5%	-$184K
Capital Expenditures	$9K-56.2%	$21K-5.0%	$23K	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	-$2.1M+45.9%	-$3.8M-119.6%	-$1.7M	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$491K+104.9%	-$10.0M-44374.0%	-$23K	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$920K-89.2%	$8.5M	$0-100.0%	$11.9M+4338.4%	$267K	N/A	$150K	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

APUS Financial Ratios

Metric	FY25	FY24	FY23
Gross Margin	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A
Return on Equity	-3.9%	N/A	-2440.3%
Return on Assets	-3.7%	N/A	-184.3%
Current Ratio	1.31+1.3	0.01-3.4	3.42
Debt-to-Equity	0.07+1.1	-1.01-13.3	12.24
FCF Margin	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-27.7%	N/A	-21.8%+5.5pp	-27.3%	N/A	N/A	N/A	N/A
Return on Assets	-24.8%	N/A	-19.3%+6.0pp	-25.2%+129.6pp	-154.8%	N/A	N/A	N/A
Current Ratio	0.90-0.4	1.31-7.0	8.34-4.5	12.79+12.6	0.15+0.1	0.01	N/A	N/A
Debt-to-Equity	0.12+0.0	0.07-0.1	0.13+0.1	0.08+1.2	-1.15-0.1	-1.01	N/A	N/A
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Aytu Biopharma Inc AYTU

$23.6M

Talphera Inc TLPH

$70.6M

Gelteq Limited GELS

$5.8M

Flora Growth Corp FLGC

$21.6M

Therapeuticsmd Inc TXMD

$23.3M

Frequently Asked Questions

Is APIMEDS PHARMACEUTICALS US INC profitable?

No, APIMEDS PHARMACEUTICALS US INC (APUS) reported a net income of -$6.0M in fiscal year 2025.

What is APIMEDS PHARMACEUTICALS US INC's EBITDA?

APIMEDS PHARMACEUTICALS US INC (APUS) had EBITDA of -$11.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is APIMEDS PHARMACEUTICALS US INC's return on equity (ROE)?

APIMEDS PHARMACEUTICALS US INC (APUS) has a return on equity of -3.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is APIMEDS PHARMACEUTICALS US INC's free cash flow?

APIMEDS PHARMACEUTICALS US INC (APUS) generated -$9.0M in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is APIMEDS PHARMACEUTICALS US INC's operating cash flow?

APIMEDS PHARMACEUTICALS US INC (APUS) generated -$8.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are APIMEDS PHARMACEUTICALS US INC's total assets?

APIMEDS PHARMACEUTICALS US INC (APUS) had $164.2M in total assets as of fiscal year 2025, including both current and long-term assets.

What are APIMEDS PHARMACEUTICALS US INC's capital expenditures?

APIMEDS PHARMACEUTICALS US INC (APUS) invested $57K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does APIMEDS PHARMACEUTICALS US INC spend on research and development?

APIMEDS PHARMACEUTICALS US INC (APUS) invested $1.6M in research and development during fiscal year 2025.

How many shares does APIMEDS PHARMACEUTICALS US INC have outstanding?

APIMEDS PHARMACEUTICALS US INC (APUS) had 13M shares outstanding as of fiscal year 2025.

What is APIMEDS PHARMACEUTICALS US INC's current ratio?

APIMEDS PHARMACEUTICALS US INC (APUS) had a current ratio of 1.31 as of fiscal year 2025, which is considered adequate.

What is APIMEDS PHARMACEUTICALS US INC's debt-to-equity ratio?

APIMEDS PHARMACEUTICALS US INC (APUS) had a debt-to-equity ratio of 0.07 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is APIMEDS PHARMACEUTICALS US INC's return on assets (ROA)?

APIMEDS PHARMACEUTICALS US INC (APUS) had a return on assets of -3.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is APIMEDS PHARMACEUTICALS US INC's cash runway?

Based on fiscal year 2025 data, APIMEDS PHARMACEUTICALS US INC (APUS) had $1.6M in cash against an annual operating cash burn of $8.9M. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is APIMEDS PHARMACEUTICALS US INC's Piotroski F-Score?

APIMEDS PHARMACEUTICALS US INC (APUS) has a Piotroski F-Score of 1 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are APIMEDS PHARMACEUTICALS US INC's earnings high quality?

APIMEDS PHARMACEUTICALS US INC (APUS) has an earnings quality ratio of 1.49x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can APIMEDS PHARMACEUTICALS US INC cover its interest payments?

APIMEDS PHARMACEUTICALS US INC (APUS) has an interest coverage ratio of -42.1x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.